NSPR vs. CLPT, OM, RXST, NPCE, NNOX, NYXH, DRTS, STIM, ZIMV, and SMTI
Should you be buying InspireMD stock or one of its competitors? The main competitors of InspireMD include ClearPoint Neuro (CLPT), Outset Medical (OM), RxSight (RXST), NeuroPace (NPCE), Nano-X Imaging (NNOX), Nyxoah (NYXH), Alpha Tau Medical (DRTS), Neuronetics (STIM), ZimVie (ZIMV), and Sanara MedTech (SMTI). These companies are all part of the "medical equipment" industry.
InspireMD vs. Its Competitors
ClearPoint Neuro (NASDAQ:CLPT) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.
ClearPoint Neuro presently has a consensus target price of $25.00, indicating a potential upside of 122.62%. InspireMD has a consensus target price of $4.50, indicating a potential upside of 85.19%. Given ClearPoint Neuro's higher probable upside, analysts clearly believe ClearPoint Neuro is more favorable than InspireMD.
In the previous week, ClearPoint Neuro had 2 more articles in the media than InspireMD. MarketBeat recorded 3 mentions for ClearPoint Neuro and 1 mentions for InspireMD. ClearPoint Neuro's average media sentiment score of 1.27 beat InspireMD's score of 0.00 indicating that ClearPoint Neuro is being referred to more favorably in the media.
ClearPoint Neuro has a net margin of -64.51% compared to InspireMD's net margin of -413.96%. InspireMD's return on equity of -69.42% beat ClearPoint Neuro's return on equity.
ClearPoint Neuro has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, InspireMD has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500.
ClearPoint Neuro has higher revenue and earnings than InspireMD. ClearPoint Neuro is trading at a lower price-to-earnings ratio than InspireMD, indicating that it is currently the more affordable of the two stocks.
30.1% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 44.8% of InspireMD shares are owned by institutional investors. 7.0% of ClearPoint Neuro shares are owned by insiders. Comparatively, 34.1% of InspireMD shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
ClearPoint Neuro beats InspireMD on 10 of the 15 factors compared between the two stocks.
Get InspireMD News Delivered to You Automatically
Sign up to receive the latest news and ratings for NSPR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InspireMD Competitors List
Related Companies and Tools
This page (NYSE:NSPR) was last updated on 7/26/2025 by MarketBeat.com Staff
Free NSPR Stock Alerts